Liangpei Gene Biotechnology (Wuhan) Co., Ltd.

Liangpei Gene Biotechnology (Wuhan) Co., Ltd. is a biopharmaceutical high-tech enterprise invested and established by Wuhan Benhui High-tech Industry Investment Co., Ltd. The company is located in the Overseas Chinese Pioneer Park of Biolake in East Lake High-tech Development Zone, Wuhan. The company has specially appointed Dr. Ye Zi, a senior scientist in the fields of high-throughput gene sequencing and clinical disease detection, as Technical Director, and has introduced the technical team of Primbio Research Institute (USA) as technical support. It is professionally engaged in the research and development of disease-related gene chip products and gene testing services.
In recent years, the rapid development of high-throughput genome sequencing technology has set off a wave of personal genome research and personalized medicine. Its wide application in the fields of clinical disease diagnosis and auxiliary diagnosis, disease risk prediction, and drug efficacy monitoring has had a profound impact on traditional medical models and human lifestyles. Primbio Research Institute (USA) is a research institution engaged in the research of gene chip and gene testing technology for many years, focusing on the application of genomics technology in the field of human health. It has a strong scientific research team in the United States and has extensive cooperation and exchanges with universities, medical and scientific research institutions around the world. Relying on the technical advantages of Primbio Research Institute (USA), Liangpei Gene possesses an advanced high-throughput sequencing platform. The main projects currently carried out include the presetting and customization of tumor hotspot gene chips, circulating tumor DNA detection in peripheral blood, auxiliary detection for personalized treatment plans, prenatal/preimplantation chromosomal abnormality screening, single-gene genetic disease screening, as well as RNA and exome sequencing, etc. It can provide domestic and foreign universities, scientific research institutes, pharmaceutical R&D enterprises and other institutions with a full set of services for high-throughput gene sequencing and clinical disease detection.
Liangpei Gene adheres to the ideological concept that "the people's aspiration for a better life is our goal." It is professionally engaged in the research and detection of clinical molecular biology and cytogenetics, focusing on genomics technology serving human health, especially in the applications of disease risk prediction, pathogenic microorganism detection, clinical diagnosis, prenatal and postnatal care, and individualized cancer diagnosis and treatment, making cutting-edge technology serve public health and sharing the core of human health with you.
With the development of business, the company urgently needs elites to join. Liangpei Gene sincerely welcomes outstanding talents to join us and create a better future together.